The Development of β-Lactam Antibiotics in Response to the Evolution of β-Lactamases

@article{Essack2004TheDO,
  title={The Development of $\beta$-Lactam Antibiotics in Response to the Evolution of $\beta$-Lactamases},
  author={Sabiha Yusuf Essack},
  journal={Pharmaceutical Research},
  year={2004},
  volume={18},
  pages={1391-1399}
}
  • S. Essack
  • Published 1 October 2001
  • Biology, Chemistry
  • Pharmaceutical Research
Abstractβ-Lactam antibiotics, viz., penicillin, penicillin derivatives, cephalosporins, cephamycins, carbapenems, monobactams, and monocarbams, are the most widely used of all antimicrobial classes by virtue of their high efficacy and specificity and the availability of several derivatives. The expression of one or several β-lactamases (β-lactam antibiotic-inactivating enzymes) represents the most widespread and the most clinically relevant resistance mechanism to these antibiotics. The… 

Exploitation of Antibiotic Resistance as a Novel Drug Target: Development of a β-Lactamase-Activated Antibacterial Prodrug

TLDR
The development of an antibiotic prodrug that combines ciprofloxacin with a β-lactamase-cleavable motif is described, paving the way for selective targeting of drug-resistant pathogens without disrupting or selecting for resistance within the microbiota.

Antibacterial and β‐Lactamase Inhibitory Activity of Monocyclic β‐Lactams

TLDR
The main goal was the derivatization of the azetidin‐2‐one core in order to improve their antibacterial potency, broaden their spectrum of activity, and enhance their β‐lactamase stability.

Extended-Spectrum Beta-Lactamase Producing Escherichia coli : Increasing Incidence of a Resistant Pathogen

TLDR
It is important to note that there are many different types of ESBL enzymes and the susceptibility profile of a given clinical isolate will depend on the specific enzyme present.

Optimizing cell permeation of an antibiotic resistance inhibitor for improved efficacy.

TLDR
Modulated the properties of this lead to enhance its ability to cross the membrane, using a combination of X-ray crystallography, structure-based design, and application of physical models of outer membrane crossing, leading to derivatives with substantially improved permeability.

Investigation of the in vivo interaction between β-lactamase and its inhibitor protein

TLDR
Although co-expression of β-lactamase and BLIP and its protein inhibitor did not completely impair cell growth, the specificity of BLIP enabled it to bindβ-lacticamase in the bacterial periplasm, regardless of the crowding components.

Structure-Based Optimization of a Non-β-lactam Lead Results in Inhibitors That Do Not Up-Regulate β-Lactamase Expression in Cell Culture

TLDR
To understand the origins of this improved activity, the structures of AmpC in complex with compound 10 and an analogue, compound 11, were determined by X-ray crystallography to 1.97 and 1.96 A, respectively.

Biochemical Characterization of CTX-M-15 from Enterobacter cloacae and Designing a Novel Non-β-Lactam-β-Lactamase Inhibitor

TLDR
It is found that tazobactam is the best among these inhibitors against CTX-M-15, and ZINC03787097 compound can be used as seed molecule to design more efficient non-β- lactam containing β-lactamase inhibitor that could evade pre-existing bacterial resistance mechanisms.

Piperacillin–tazobactam: a β-lactam/β-lactamase inhibitor combination

TLDR
Clinical trials have demonstrated piperacillin–tazobactam to be effective for the treatment of patients with intra-abdominal infections, skin and soft tissue infections, lower respiratory tract infections, complicated urinary tract infections and gynecological infections and more recently, febrile neutropenia.

Design, Development and Synthesis of Novel Cephalosporin Group of Antibiotics

TLDR
Even though the cephalosporin antibiotics have made remarkable progress and contribution in the treatment of acute diseases originated from pathogenic infection in clinics, many efforts still exist to achieve the well balanced broad spectrum and to improve beta-lactamase stability.
...

References

SHOWING 1-10 OF 100 REFERENCES

Meeting the challenges of beta-lactamases.

  • R. Moellering
  • Biology, Medicine
    The Journal of antimicrobial chemotherapy
  • 1993
TLDR
The nature of these enzymes is defined and the attempts to overcome the problem of resistance mediated by beta-lactamase are detailed, efforts which have culminated in the development of a series of effectivebeta-lacticamase inhibitors which can be combined with beta- lactam antibiotics.

Bacterial Resistance to β-Lactam Antibiotics

TLDR
The clinical and economic consequences of therapeutic failure and relapse--extended hospital stays, increased morbidity and mortality, and the use of potentially more toxic and costly antimicrobial agents--require new strategies to prevent the spread of resistant organisms and to limit future resistance.

New beta-lactamases in gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy.

  • K. Bush
  • Biology, Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2001
Of the 340 discrete beta-lactamases that have been identified, the most important groups of enzymes that are continuing to proliferate include the plasmid-encoded cephalosporinases, the

Meeting the challenges of β-lactamases

TLDR
The nature of these enzymes is defined and the attempts to overcome the problem of resistance mediated by β-lactamase are detailed, efforts which have culminated in the development of a series of effectiveβ-l lactamase inhibitors which can be combined with β- lactam antibiotics.

Evolution and dissemination of beta-lactamases accelerated by generations of beta-lactam antibiotics.

  • A. Medeiros
  • Biology, Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 1997
TLDR
The structure and evolution of beta-lactamases are reviewed in an attempt to understand the pressures that have contributed to their emergence.

Perspectives of beta-lactamases inhibitors in therapy of infections caused by Escherichia coli or Klebsiella with plasmidic resistance to third generation cephalosporins

SummaryNew plasmidic β-lactamases inactivating so far stable cephalosporins, aztreonam and cephamycins restrict the use of these antibiotics in therapy of infections, e.g., byEscherichia coli and

beta-Lactamases in laboratory and clinical resistance

  • D. Livermore
  • Biology, Medicine
    Clinical microbiology reviews
  • 1995
TLDR
The ability of the prevalent beta-Lactamases to cause resistance to widely used beta-lactams, whether resistance is accurately reflected in routine tests, and the extent to which the antibiogram for an organism can be used to predict the type of beta- lactamase that it produces are considered.

Bacterial resistance to beta-lactam antibiotics.

  • L. DanzigerS. Pendland
  • Medicine, Biology
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 1995
TLDR
The clinical and economic consequences of therapeutic failure and relapse--extended hospital stays, increased morbidity and mortality, and the use of potentially more toxic and costly antimicrobial agents--require new strategies to prevent the spread of resistant organisms and to limit future resistance.

Catalytic properties of class A beta-lactamases: efficiency and diversity.

TLDR
Despite the many available kinetic, structural and mutagenesis data, the factors explaining the diversity of the specificity profiles of class A beta-lactamases and their amazing catalytic efficiency have not been thoroughly elucidated.
...